Stoke Therapeutics and Biogen to present four-year zorevunersen data at epilepsy congress
Stoke Therapeutics (STOK) and Biogen (BIIB) will present four-year data on zorevunersen, their experimental Dravet syndrome treatment, at the European Epilepsy Congress. The data shows sustained cognitive and behavioral improvements, reduced seizures, and a generally safe profile. 77% of patients remain in extension studies. Zorevunersen is in Phase 3 trials, with results expected in Q3 2027. The therapy has received FDA and EMA designations but is not yet approved.
How this was made
The 30-second read
Why it matters
The four-year extension data provide the first long‑term efficacy and safety readout, a material update for both companies.
Market read
Long‑term trial data for a rare‑disease therapy can shift investor sentiment and affect peer valuations in the neurology biotech space.
What to watch
Regulatory timelines and commercial partnership terms could dampen near‑term price moves despite positive data.
Background
Stoke Therapeutics and Biogen are co‑developing zorevunersen, an antisense oligonucleotide for Dravet syndrome, which has Breakthrough Therapy and orphan designations.
Ticker impact
Stoke Therapeutics will present four-year Phase 1/2a extension data for zorevunersen at the European Epilepsy Congress.
Potential modest upside for STOK as data confirms sustained efficacy and safety.
Four-year extension results are a primary disclosure for a biotech with breakthrough designation; such data often move the stock.
Biogen, partner on zorevunersen, will co‑present the same four-year data at the congress.
Likely modest upside for BIIB, especially in the neurology segment.
Biogen's co‑development role makes the data material; investors watch partner trial outcomes closely.
Market effects
Strengthens the neurology/rare‑disease biotech sector and may influence peer valuations.
Highlights European conference as a venue for key data releases, modestly affecting EU biotech sentiment.
Adds to global pipeline confidence for antisense therapies targeting SCN1A.
Counterpoint
Data may be over‑interpreted; long‑term safety concerns could emerge later, limiting upside.
Key entities
- CompanyStoke Therapeutics
Biotech developing zorevunersen, US‑listed on NASDAQ.
- CompanyBiogen
Global biotech partner, US‑listed on NASDAQ.
